$227 Million is the total value of GREAT POINT PARTNERS LLC's 35 reported holdings in Q1 2015. The portfolio turnover from Q4 2014 to Q1 2015 was 100.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
PLX | Exit | PROTALIX BIOTHERAPEUTICS INC | $0 | – | -213,215 | -100.0% | -0.19% | – |
ANTH | Exit | ANTHERA PHARMACEUTICALS INC | $0 | – | -250,000 | -100.0% | -0.19% | – |
ZGNX | Exit | ZOGENIX INC | $0 | – | -367,502 | -100.0% | -0.24% | – |
NBIX | Exit | NEUROCRINE BIOSCIENCES INCput | $0 | – | -46,200 | -100.0% | -0.50% | – |
ONTX | Exit | ONCONOVA THERAPEUTICS INC | $0 | – | -553,079 | -100.0% | -0.88% | – |
EXEL | Exit | EXELIXIS, INC | $0 | – | -2,233,711 | -100.0% | -1.55% | – |
AGEN | Exit | AGENUS INC | $0 | – | -920,300 | -100.0% | -1.76% | – |
SYN | Exit | SYNTHETIC BIOLOGICS INC | $0 | – | -3,998,941 | -100.0% | -2.81% | – |
ARWR | Exit | ARROWHEAD RESH CORP | $0 | – | -1,126,835 | -100.0% | -4.00% | – |
ELGX | Exit | ENDOLOGIX INC | $0 | – | -650,000 | -100.0% | -4.78% | – |
INFI | Exit | INFINITY PHARMACEUTICALS INC | $0 | – | -625,000 | -100.0% | -5.08% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-05-15
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
STREAMLINE HEALTH SOLUTNS, INC CMN | 25 | Q3 2019 | 2.5% |
IOVANCE BIOTHERAPEUTICS, INC. CMN | 16 | Q1 2021 | 14.3% |
ZOGENIX INC CMN | 16 | Q4 2019 | 8.8% |
PTC THERAPEUTICS, INC. CMN | 16 | Q3 2023 | 9.9% |
EXELIXIS, INC | 16 | Q1 2022 | 7.5% |
SAGE THERAPEUTICS, INC CMN | 15 | Q3 2021 | 10.8% |
CYTOKINETICS INC | 15 | Q3 2023 | 5.8% |
ACADIA PHARMACEUTICALS, INC. | 14 | Q1 2021 | 8.8% |
ACCELERON PHARMA INC CMN | 14 | Q2 2020 | 8.2% |
CONNECTURE INC | 13 | Q4 2017 | 25.1% |
View GREAT POINT PARTNERS LLC's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
89bio, Inc. | February 14, 2023 | 700,000 | 1.4% |
KalVista Pharmaceuticals, Inc. | February 14, 2023 | 1,055,801 | 3.1% |
Avalo Therapeutics, Inc. | February 13, 2023 | 974,639 | 7.1% |
InflaRx N.V.Sold out | February 14, 2022 | 0 | 0.0% |
ABEONA THERAPEUTICS INC.Sold out | February 16, 2021 | 0 | 0.0% |
CONSTELLATION PHARMACEUTICALS INC | February 16, 2021 | 1,024,800 | 2.2% |
GERON CORP | February 16, 2021 | 12,754,228 | 4.0% |
Millendo Therapeutics, Inc. | February 16, 2021 | 270,000 | 1.4% |
NextCure, Inc.Sold out | February 16, 2021 | 0 | 0.0% |
PROTHENA CORP PUBLIC LTD CO | February 16, 2021 | 977,647 | 2.4% |
View GREAT POINT PARTNERS LLC's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
SC 13G | 2024-04-08 |
13F-HR | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
View GREAT POINT PARTNERS LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.